



DIABIZ-GM TABLETS

Issue I , No3., 2025

Analysis of phase 3 study of fixed-dose combination of Dapagliflozin, Glimepiride and Metformin IR in type 2 diabetes mellitus patients aged

Kurmi P, et al. Diabetes, Obesity, Metabolism and Nutrition; Endocrine Abstracts (2024) 99 EP337

- Fixed-dose combination (FDC) of Dapagliflozin+Metformin+Sulfonylurea with complementary mechanisms can provide effective glycemic control, preserve beta-cell function, improved compliance without risk of weight gain, and reno-protective action in type 2 diabetes mellitus.
- This subgroup analysis evaluated glycemic and safety parameters from Baseline till Week 28 in two age subgroups; subgroup 1 (S1:age <45 years) & subgroup 2 (S2:age 45-65 years). At baseline, 223 patients aged <45 years (S1) and 310 patients aged 45-65 years (S2).
- Significant reduction in HbA1c, fasting and post prandial blood glucose was observed from Baseline to Weeks 12 and 16 in each arm in both subgroups.
- No patient reported hypoglycaemia & both groups tolerated the treatment with FDCs.

Triple FDCs of Dapagliflozin+Glimepiride+Metformin showed statistically significant reduction in HbA1c from Baseline to Week 16 as compared to dual combinations in T2DM patients of both age groups (<45 years and 45-65 years) and is a treatment option for all age groups.

